Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) EBT (2017 - 2025)

Historic EBT for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$56.9 million.

  • Sutro Biopharma's EBT fell 1654.13% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$203.8 million, marking a year-over-year decrease of 8845.09%. This contributed to the annual value of -$225.1 million for FY2024, which is 15405.81% down from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's EBT is -$56.9 million, which was down 1654.13% from -$11.5 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's EBT peaked at $46.9 million during Q4 2023, and registered a low of -$70.1 million during Q4 2024.
  • Over the past 5 years, Sutro Biopharma's median EBT value was -$38.4 million (recorded in 2023), while the average stood at -$34.7 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 28218.47% in 2022, then skyrocketed by 23549.17% in 2023.
  • Sutro Biopharma's EBT (Quarter) stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then soared by 235.49% to $46.9 million in 2023, then plummeted by 249.53% to -$70.1 million in 2024, then grew by 18.88% to -$56.9 million in 2025.
  • Its last three reported values are -$56.9 million in Q3 2025, -$11.5 million for Q2 2025, and -$65.3 million during Q1 2025.